Company: IMRX
Filing Date: 2025-03-20
Form Type: 10-K
Source: 0001790340-25-000042
Chunk: 108

Company: Immuneering Corp
Filing Date: 2025-03-20
Form: 10-K
Item: Item 8
Chunk 108
---
503 Long-term liabilities:  Lease liabilities, net of current portion3,824,419 4,162,852 Total liabilities11,328,187 12,008,355 Commitments and contingencies (Note 11)  Stockholders’ equity:  Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2024 and December 31, 2023; 0 shares issued or outstanding at December 31, 2024 and December 31, 2023— — Class A common stock, $0.001 par value, 200,000,000 shares authorized at December 31, 2024 and December 31, 2023; 31,050,448 and 29,271,629 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively31,050 29,272 Class B common stock, $0.001 par value, 20,000,000 shares authorized at December 31, 2024 and December 31, 2023; 0 shares issued and outstanding at December 31, 2024 and December 31, 2023— — Additional paid-in capital265,650,362 253,806,267 Accumulated other comprehensive loss— (778)Accumulated deficit(224,295,186)(163,258,578)Total stockholders' equity 41,386,226 90,576,183 Total liabilities and stockholders' equity $52,714,413 $102,584,538 

The accompanying notes are an integral part of these consolidated financial statements.

120

IMMUNEERING CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023

Year Ended December 31, 20242023Operating expenses  Research and development$47,964,388 $41,624,018 General and administrative16,077,746 16,759,602 Amortization of intangible asset29,267 29,267 Total operating expenses64,071,401 58,412,887 Loss from operations(64,071,401)(58,412,887)Other income (expense)  Interest income2,593,300